

## CLAIMS

1. A DNA containing uncoupling protein-2 (UCP-2) promoter region containing the regulator sequence.

5

2. A DNA described in claim 1 wherein the regulator sequence is a sequence containing peroxisome proliferator response element (PPRE).

10 3. A DNA described in claim 1 wherein the regulator sequence is a sequence containing CCAAT/enhancer binding protein (C/EBP) binding sequence.

15 4. A DNA described in claim 1 wherein the promoter region is a base sequence presented by position 1 to 2270 of SEQ ID NO: 1 or a base sequence containing a part of the said base sequence.

20 5. A recombinant vector containing a DNA described in claim 1.

6. A recombinant vector described in claim 5 containing a DNA containing a structural gene under control of UCP-2 promoter region containing a regulator sequence.

25

7. A transformant transformed by a recombinant vector described in claim 5.

30 8. A method for screening a compound or its salt that promotes or inhibits UCP-2 promoter activity characterized by use of a transformant described in claim 7.

35 9. A method for screening a compound or its salt that promotes or inhibits heat production characterized by

00569058-092001

use of a transformant described in claim 7.

10. A method for screening an antiobestic drug, an  
antidiabetic drug, a depressor, an antihyperlipemic  
5 drug, and an antipyretic drug characterized by use of a  
transformant described in claim 7.

11. A kit for screening a compound or its salt that  
promotes or inhibits UCP-2 promoter activity  
10 characterized by use of a transformant described in  
claim 7.

12. A compound or its salt that promotes or inhibits  
UCP-2 promoter activity obtained using a screening  
15 method described in claim 8 or a screening kit  
described in claim 11.

13. A compound or its salt that promotes or inhibits  
heat production obtained using a screening method  
20 described in claim 9.

14. A pharmaceutical composition containing a compound  
or its salt that promotes or inhibits UCP-2 promoter  
activity obtained using a screening method described in  
25 claim 8 or a screening kit described in claim 11.

00250-0509001